Literature DB >> 3240705

Comparative in vitro potencies of nine new macrolides.

P B Fernandes1, D J Hardy.   

Abstract

The in vitro activities of the 14-membered macrolides (14M) clarithromycin (CL), roxithromycin (RO), dirithromycin (DI) and flurithromycin (FL), a 15-membered macrolide (15M) azithromycin (AZ), and the 16-membered macrolides (16M) josamycin (JM), spiramycin (SP), miocamycin (MI) and rokitamycin (RK) were compared with erythromycin (ER). CL was two- to four-fold more potent than ER against all organisms except Haemophilus and Campylobacter jejuni against which it was two-fold less active. RO and DI were generally two- to four-fold less active than ER. FL was two-fold less active than ER. AZ was equal to or two-fold less active than ER against Gram-positive bacteria and two- to four-fold more active than ER against Gram-negative bacteria, such as Haemophilus, Neisseria gonorrhoeae and Branhamella. The 16M were generally four- to eight-fold less active than ER against most aerobic bacteria and two-fold less active than ER against anaerobic bacteria. RK was generally two-fold more active than the other 16M. Bacteria carrying a constitutive-type of MLS resistance were resistant to the 14M, 15M and 16M, whereas bacteria with an inducible-type of resistance were susceptible to the 16M but resistant to the 14M and 15M. Addition of serum to the medium increased the activity of ER, CL, DI, FL, AZ and SP. The activity of RO was reduced four- to six-fold and the activity of MI was reduced by two-fold by adding serum to the medium. The activity of JO was unaffected by serum. All the macrolides were one- to four-fold more active at pH 8.0 than at pH 6.5. All the macrolides were bacteriostatic against Staphylococcus aureus 553, except RO and MI which were slowly bactericidal. All the macrolides were slowly bactericidal against Haemophilus influenzae 1435.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3240705

Source DB:  PubMed          Journal:  Drugs Exp Clin Res        ISSN: 0378-6501


  14 in total

Review 1.  The macrolide antibiotic renaissance.

Authors:  George P Dinos
Journal:  Br J Pharmacol       Date:  2017-08-10       Impact factor: 8.739

Review 2.  Clarithromycin and omeprazole as helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders.

Authors:  A Markham; D McTavish
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

3.  Synthesis and antimicrobial evaluation of dirithromycin (AS-E 136; LY237216), a new macrolide antibiotic derived from erythromycin.

Authors:  F T Counter; P W Ensminger; D A Preston; C Y Wu; J M Greene; A M Felty-Duckworth; J W Paschal; H A Kirst
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

Review 4.  Clarithromycin clinical pharmacokinetics.

Authors:  F Fraschini; F Scaglione; G Demartini
Journal:  Clin Pharmacokinet       Date:  1993-09       Impact factor: 6.447

Review 5.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

Review 6.  Miocamycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.

Authors:  S M Holliday; D Faulds
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

7.  Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension.

Authors:  M C Nahata; K I Koranyi; S D Gadgil; D M Hilligoss; H G Fouda; M J Gardner
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

8.  Comparative in vitro activity of clarithromycin. Spanish Collaborative Group.

Authors:  E Loza; J Martínez Beltrán; F Baquero; A León; R Cantón; B Garijo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-09       Impact factor: 3.267

9.  Comparative pharmacodynamics of clarithromycin and azithromycin against respiratory pathogens.

Authors:  A Bauernfeind; R Jungwirth; E Eberlein
Journal:  Infection       Date:  1995 Sep-Oct       Impact factor: 3.553

Review 10.  Dirithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D H Peters
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.